Sath Shukla, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 121,087 shares at $1.45 ($173K) on 2024-02-05, disclosed to the SEC on 2024-02-05.
Scheduled sale ($173k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.37 | 30,901 | $42K | 24.5% |
| 2 | $1.45 | 45,093 | $65K | 37.8% |
| 3 | $1.45 | 45,093 | $65K | 37.8% |
| Total | $1.43 avg | 121,087 | $173K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-06 | $43K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $8K | — | Filing → |
| SPRO | SELL | 2023-02-03 | $17K | — | Filing → |